Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load
Background/aims The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the u...
Published in: | British Journal of Ophthalmology |
---|---|
Main Authors: | , , , , , , |
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group Ltd
2011
|
Subjects: | |
Online Access: | http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300304v1 https://doi.org/10.1136/bjophthalmol-2011-300304 |
id |
fthighwire:oai:open-archive.highwire.org:bjophthalmol:bjophthalmol-2011-300304v1 |
---|---|
record_format |
openpolar |
spelling |
fthighwire:oai:open-archive.highwire.org:bjophthalmol:bjophthalmol-2011-300304v1 2023-05-15T16:48:01+02:00 Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load Geirsdottir, Asbjorg Jonsson, Oskar Thorisdottir, Sigridur Helgadottir, Gudleif Jonasson, Fridbert Stefansson, Einar Sigurdsson, Haraldur 2011-08-19 01:24:19.0 text/html http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300304v1 https://doi.org/10.1136/bjophthalmol-2011-300304 en eng BMJ Publishing Group Ltd http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300304v1 http://dx.doi.org/10.1136/bjophthalmol-2011-300304 Copyright (C) 2011, BMJ Publishing Group Ltd Original articles - Clinical science TEXT 2011 fthighwire https://doi.org/10.1136/bjophthalmol-2011-300304 2015-02-28T15:00:17Z Background/aims The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the use of intravitreal ranibizumab in a defined population. Methods This is a prospective study of 439 consecutive patients aged 60 years and older with exudative AMD starting intravitreal ranibizumab for exudative AMD in Iceland from March 2007 to December 2009. All patients initially received three consecutive ranibizumab injections, with regular follow-up visits and re-treatment as needed. Results In total, 517 eyes from 439 patients received treatment for exudative AMD (mean age 79 years). The annual incidence of exudative AMD in the population 60 years and older is 0.29%. The incidence increased with advancing age, double for patients 85 years and older compared with those 75–79 years. Approximately 2400 ranibizumab injections per 100 000 persons aged 60 years and older were given each year for exudative AMD. Conclusions These data allow an estimation of the incidence of exudative AMD in a Caucasian population and the treatment load with ranibizumab, which may help plan anti-vascular endothelial growth factor treatment programmes and estimate costs. Text Iceland HighWire Press (Stanford University) British Journal of Ophthalmology 96 3 444 447 |
institution |
Open Polar |
collection |
HighWire Press (Stanford University) |
op_collection_id |
fthighwire |
language |
English |
topic |
Original articles - Clinical science |
spellingShingle |
Original articles - Clinical science Geirsdottir, Asbjorg Jonsson, Oskar Thorisdottir, Sigridur Helgadottir, Gudleif Jonasson, Fridbert Stefansson, Einar Sigurdsson, Haraldur Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
topic_facet |
Original articles - Clinical science |
description |
Background/aims The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the use of intravitreal ranibizumab in a defined population. Methods This is a prospective study of 439 consecutive patients aged 60 years and older with exudative AMD starting intravitreal ranibizumab for exudative AMD in Iceland from March 2007 to December 2009. All patients initially received three consecutive ranibizumab injections, with regular follow-up visits and re-treatment as needed. Results In total, 517 eyes from 439 patients received treatment for exudative AMD (mean age 79 years). The annual incidence of exudative AMD in the population 60 years and older is 0.29%. The incidence increased with advancing age, double for patients 85 years and older compared with those 75–79 years. Approximately 2400 ranibizumab injections per 100 000 persons aged 60 years and older were given each year for exudative AMD. Conclusions These data allow an estimation of the incidence of exudative AMD in a Caucasian population and the treatment load with ranibizumab, which may help plan anti-vascular endothelial growth factor treatment programmes and estimate costs. |
format |
Text |
author |
Geirsdottir, Asbjorg Jonsson, Oskar Thorisdottir, Sigridur Helgadottir, Gudleif Jonasson, Fridbert Stefansson, Einar Sigurdsson, Haraldur |
author_facet |
Geirsdottir, Asbjorg Jonsson, Oskar Thorisdottir, Sigridur Helgadottir, Gudleif Jonasson, Fridbert Stefansson, Einar Sigurdsson, Haraldur |
author_sort |
Geirsdottir, Asbjorg |
title |
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
title_short |
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
title_full |
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
title_fullStr |
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
title_full_unstemmed |
Population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
title_sort |
population-based incidence of exudative age-related macular degeneration and ranibizumab treatment load |
publisher |
BMJ Publishing Group Ltd |
publishDate |
2011 |
url |
http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300304v1 https://doi.org/10.1136/bjophthalmol-2011-300304 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://bjo.bmj.com/cgi/content/short/bjophthalmol-2011-300304v1 http://dx.doi.org/10.1136/bjophthalmol-2011-300304 |
op_rights |
Copyright (C) 2011, BMJ Publishing Group Ltd |
op_doi |
https://doi.org/10.1136/bjophthalmol-2011-300304 |
container_title |
British Journal of Ophthalmology |
container_volume |
96 |
container_issue |
3 |
container_start_page |
444 |
op_container_end_page |
447 |
_version_ |
1766038103709974528 |